287944-16-5

Usage

Uses

Used in Organic Synthesis:
3,6-Dihydro-2H-pyran-4-boronic acid pinacol ester is used as an intermediate in organic synthesis for the development of agrochemicals, pharmaceuticals, and dyes. Its unique structure allows for the formation of new compounds with potential applications in these industries.
Used in Agrochemical Industry:
In the agrochemical industry, 3,6-Dihydro-2H-pyran-4-boronic acid pinacol ester is used as an intermediate for the synthesis of new agrochemicals. Its reactivity and functional groups enable the creation of compounds with potential pesticidal or herbicidal properties.
Used in Pharmaceutical Industry:
3,6-Dihydro-2H-pyran-4-boronic acid pinacol ester is used as an intermediate in the pharmaceutical industry for the synthesis of new drug candidates. Its unique structure can be utilized to develop compounds with potential therapeutic effects.
Used in Dye Industry:
In the dye industry, 3,6-Dihydro-2H-pyran-4-boronic acid pinacol ester is used as an intermediate for the synthesis of new dyes. Its functional groups can be exploited to create dyes with specific color properties and stability.
Used in the Synthesis of 1,2-Dihydro-2-Oxopyridine Based Endocannabinoid System (ECS) Modulators:
3,6-Dihydro-2H-pyran-4-boronic acid pinacol ester is used as a key intermediate in the preparation of 1,2-dihydro-2-oxopyridine based endocannabinoid system (ECS) modulators. These modulators have potential applications in the treatment of various medical conditions related to the ECS.
Used in the Synthesis of Embryonic Ectoderm Development (EED) Inhibitors:
3,6-Dihydro-2H-pyran-4-boronic acid pinacol ester is used as an intermediate in the synthesis of embryonic ectoderm development (EED) inhibitors. These inhibitors have potential applications in the study and treatment of developmental disorders.
Used in the Preparation of Pyrrolotriazine Based IRAK4 Inhibitors:
3,6-Dihydro-2H-pyran-4-boronic acid pinacol ester is used in the preparation of pyrrolotriazine based IRAK4 inhibitors. These inhibitors have potential applications in the treatment of inflammatory and autoimmune diseases by targeting the IRAK4 enzyme.

InChI:InChI=1/C11H19BO3/c1-10(2)11(3,4)15-12(14-10)9-5-7-13-8-6-9/h5H,6-8H2,1-4H3

Upstream product

• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 188975-30-6 5,6-dihydro-4-trifluoromethylsulfonyloxy-2H-pyran 
• 73183-34-3 bis(pinacol)diborane 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 75405-45-7 4-(prop-2-en-1-yloxy)but-1-yne 
• 1295521-64-0 2-(3-allyloxy-1-methylene-propyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 24265-23-4 tetrahydropyran-4-enyl bromide 
• 141534-86-3 (dihydro-2H-pyran-4(3H)-ylidene)hydrazine 
• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 121-43-7 Trimethyl borate 
• 207611-87-8 4,4′-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,1′-biphenyl 
• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Downstream Products

• 1231926-02-5 4-(3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yloxy)aniline 
• 1231925-91-9 N-(4-(3-(3,6-dihydro-2H-pyran-4-yl)pyridin-2-yloxy)phenyl)-3-methylpyridin-2-amine 
• 1231926-00-3 N-(4-(3-(3,6-dihydro-2H-pyran-4-yl)pyrazin-2-yloxy)phenyl)-3-fluoropyridin-2-amine 
• 1241910-67-7 4-(3,6-dihydro-2H-pyran-4-yl)-3-(trifluoromethyl)benzonitrile 
• 1241909-82-9 C₂₃H₂₃N₃O₂ 
• 1295521-50-4 4-(1-(2-pyrrolidin-1-yl-ethyl)-4-(tetrahydro-pyran-4-yl)-1H-imidazol-2-yl)-piperidine 
• 1332487-79-2 (R)-((S)-5-(tert-butyldimethylsilyloxy)-4-(3,6-dihydro-2H-pyran-4-yl)-2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-3-yl)(4-(trifluoromethyl)phenyl)methanol 
• 1547460-25-2 (S)-4-(1-(2-methoxyphenyl)allyl)-3,6-dihydro-2H-pyran 
• 1547460-26-3 (S)-4-(2-methyl-5-phenylpent-1-en-3-yl)-3,6-dihydro-2H-pyran 
• 1547460-24-1 methyl (S)-2-((4-bromophenyl)(3,6-dihydro-2H-pyran-4-yl)methyl)acrylate 

Relevant academic research and scientific papers

New synthesis process of 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester

The invention relates to a new synthesis process of 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester( as shown in the formula I). The new synthesis process comprises the following steps that (1) tetrahydropyranone (as shown in the formula II) is condensed with hydrazine hydrate to generate a product, namely hydrazone (as shown in the formula III); (2) under alkaline conditions, the hydrazone (asshown in the formula III) reacts with iodine to generate a compound 4-iodo-3,6-dihydro-2H-pyran (as shown in the formula IV); (3) the compound IV and a Grignard reagent are in a Grignard exchange reaction, and then coupled with isopropoxyboronic acid pinacol ester (as shown in the formula V) to prepare a target product, namely the 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester. The synthesis process disclosed by the invention is high in yield, mild in reaction conditions, and suitable for large-scale industrial production.

5-Alkyl-2-urea-Substituted Pyridines: Identification of Efficacious Glucokinase Activators with Improved Properties

Two 1-(4-aryl-5-alkyl-pyridin-2-yl)-3-methylurea glucokinase activators were identified with robust in vivo efficacy. These two compounds possessed higher solubilities than the previously identified triaryl compounds (i.e., AM-2394). Structure-activity re

TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS

A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

A 3,6-dihydro -2H-pyran-4-boronic acid frequency method for the synthesis of ester

The invention discloses a synthetic method of 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester, which comprises the following steps: 1) carrying out a reaction of tetrahydro-4H-pyran-4-one and hydrazine hydrate in a solvent to generate single ketone hydrazone; 2) carrying out a reaction of the single ketone hydrazone and copper bromide in a solvent in the presence of triethylamine to obtain a dibromo intermediate; 3) carrying out an elimination reaction of the dibromo intermediate and an alkali in a solvent to obtain an alkenyl bromide compound; 4) carrying out a Suzuki-Miyaura reaction of the alkenyl bromide compound and bis(pinacolato)diboron in a solvent in the presence of a palladium complex to obtain the product. The synthetic method of the invention is simple, and low in cost, adopts no dangerous raw materials, and is safe and suitable for large-scale production.

Method for synthesizing 3, 6-dihydro-2H-pyrazine (thiazine) furan-4-boric acid ester

The invention discloses a method for synthesizing 3, 6-dihydro-2H-pyrazine (thiazine) furan-4-boric acid ester. According to the method, tetrahydropyrazole (thiazine) furan-4-ketone serves as the raw material, generates hydrazone with p-toluenesulfonhydrazide, then reacts with NBS/organic alkali to generate alkenyl bromide and next forms Grignard reagent with magnesium metal, after the Grignard reagent is formed, boron reagent is added for a reaction, and the 3, 6-dihydro-2H-pyrazine (thiazine) furan-4-boric acid ester is obtained. By means of the method, ultralow temperature, column chromatography and palladium catalyzed coupling in a literature method are avoided, raw materials are easy to obtain, cost is low, conditions are mild, and the method has potential industrial application and amplification prospect.

Development of an efficient process for 3,6-dihydro-2h-pyran-4-boronic acid pinacol ester

An efficient process for the synthesis of 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester has been developed in one-pot manner. Starting from the condensation of 4-tetrahydropyranone with hydrazine hydrate, the subsequent treatment of hydrazone with copper(II) bromide-triethylamine and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) conveniently gave 4-bromo-3,6-dihydro-2H-pyran, which was then conducted through palladium-catalyzed borylation to afford the desired product using a low loading of a Pd catalyst.

Novel Heterocyclic Compounds and Uses Thereof

New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

NOVEL PYRIDINE DERIVATIVES

The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS

The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

AKT INHIBITORS

The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.